Mentioned:
CNXU +2.32%

Conexeu Sciences has a bold ambition: using 3D printing to change the future of breast reconstruction.

What’s happening:

  • Conexeu Sciences (NASDAQ: CNXU) has launched a preclinical development program for their 3D printed bioregenerative breast matrix which was recently successfully printed at the Wake Forest Institute for Regenerative Medicine

Why it matters:‍

  • The Wake Forest Institute for Regenerative Medicine is one of the leading regenerative medicine research organizations in the United States of America and has previously helped advance engineered tissues and organs from initial discoveries into clinical therapies

Going deeper:‍

  • Conexeu Sciences has publicly stated that they will leverage the Wake Forest Institute for Regenerative Medicine’s advance tissue-organ bioprinting infrastructure to support a preclinical study design that evaluates the durability and host tissue integration of their 3D printed bioregenerative breast matrix that was developed using Conexeu Sciences’ patented bioregenerative extracellular matrix platform
  • The 3D printed bioregenerative breast matrix being developed by Conexeu Sciences is aiming to enable the human body to rebuild its own breast tissue to support post-mastectomy reconstruction from breast cancer, providing a temporary resorbable scaffold instead of current alternatives like permanent implants
  • Conexeu Sciences' patented bioregenerative extracellular matrix platform was developed over more than a decade of preclinical university research and has been issued patents in the United States, Japan, Australia and the European Union

The intrigue:‍

‍